榄香烯乳联合GP方案治疗晚期非小细胞肺癌

目的：探讨榄香烯乳（elemene emulsion）联合GP方案治疗晚期非小细胞肺癌（NSCLC）的临床疗效及其影响。方法：82例晚期NSCLC患者随机入组采用GP方案吉西他滨（G）＋顺铂（P）]和EGP方案榄香烯乳（E）＋GP]化疗。采用欧洲癌症研究和治疗组织的生活质量调查核心问卷（QLQ-C30）和肺癌症状量表观察者表评分,对治疗后患者的疗效、生活质量及不良反应进行评价及组间比较。结果：治疗后GP组有效率（RR）为41.5%,其中完全缓解（CR）1例,部分缓解（PR）16例;EGP组RR48.8%,CR2例,PR18例。1年和2年生存率GP组是40.0%和20.0%,EGP组为45.0%和25.0%。两组之间有效率和生存率的差异均无统计学意义（P〉0.05）。用Kaplan-Meier法描述两组的生存过程,chi2（1）=1.32,P=0.25。主要不良反应是Ⅲ~Ⅳ度骨髓抑制,治疗后GP组的白细胞减少发生率为46.3%,中性粒细胞减少发生率48.8%,血小板减少发生率36.6%,EGP组分别为17.1%、19.5%和12.2%,治疗前后两组间比较均有显著差异（P〈0.05）。肺癌症状量表观察者表评分显示,治疗后评分两组差异均有统计学意义（P〈0.05）,但呼吸困难、咯血的治疗效果GP组不如EGP组明显。结论：EGP与GP方案具有相似的疗效,但是,不良反应,特别是骨髓抑制,EGP方案比GP方案轻,因此,EGP方案治疗晚期NSCLC更容易被患者接受。

To Study Elemene Emulsion, Gemcitabine, and Cisplatin in the Treatment of Advanced Non-small Cell Lung Cancer

Objective：To explore the curative effect and other influences of elemene emulsion combined regimens containing gemcitabine and cisplatin for advanced non-small cell lung cancer（NSCLC）.Methods： A total of 82 advanced NSCLC patients were divided randomly into two groups：a regimen of GP（gemcitabine,G） plus（cisplatin,P）] and EGP （elemene emulsion,E） plus（GP）].Quality of life（QOL） was assessed by European Organization for Research and Treatment of Cancer QLQ-C30 and the observer score of lung cancer symptom scale（LCSS）.Efficacies and toxicities were analyzed and compared after chemotherapy.Results： After treatment,the response rate（RR） was 41.5% in GP group with 1 case of complete remission（CR） and 16 cases of partial remission（PR）,and 48.8% in EGP group with 2 cases of CR and 18 cases of PR.The one-year and two-year survival rates were 40.0% and 20.0% in GP group,and 45.0% and 25.0% in EGP group.The differences of RR and survival rate between the 2 groups were not significant（P0.05）.The Kaplan-Meier estimator allowed to calculate the survival curves for different times,chi2（1） = 1.32,P=0.25.The major adverse reactions wereⅢ-Ⅳdegree myelo-suppression,the rates of leucopenia,neutropenia and thrombocytopenia were 46.3%,48.8% and 36.6% in GP group and they were higher than 17.1%,19.5% and 12.2% in EGP group with a statistically significant difference（P0.05）.The observer score of lung cancer symptom scale showed that the post-treatment scores of appetite,fatigue and pain significantly improved in two groups.But therapeutic effect of dyspnea and emptysis was more significant in EGP group than in GP group（P0.05）.Conclusions： The curative efficacy were similar between EGP regimen and GP regimens,but toxicity,especially myelosuppression,was more remarkably mild in the EGP regimen than in the GP regimen,therefore,the EGP regimen would appear to be more easy to accept for the treatment of patients with advanced NSCLC.